Pharvaris N.V. — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020; filed April 29, 2021. This is an annual report, not a standalone Q4 report, and the filing does not provide separate fourth-quarter results. Financial statements are audited and prepared under IFRS in euros.
Business context
Pharvaris is a clinical-stage biopharmaceutical company developing oral PHA121-based treatments for hereditary angioedema (HAE): PHVS416 for on-demand treatment and PHVS719 for prophylaxis. It had no approved products and no product revenue in 2020. At year-end, its clinical program was in Phase 1; the Phase 2 RAPIDe-1 trial began in February 2021, after the reporting period.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | €19.5 million | €5.7 million |
| General and administrative expense | €5.5 million | €2.3 million |
| Total operating expenses | €25.0 million | €8.0 million |
| Net loss | €26.0 million | €8.0 million |
| Basic and diluted loss per share | €5.36 | €1.66 |
| Cash used in operating activities | €21.5 million | €6.7 million |
| Cash and cash equivalents at year-end | €98.6 million | €20.3 million |
| Total liabilities | €5.3 million | €1.9 million |
| Borrowings | None reported | None reported |
There was no meaningful revenue or operating margin to assess. The 2020 loss increase reflected expanded clinical and preclinical work, manufacturing and formulation development, hiring, share-based compensation, and higher public-company preparation costs. Net foreign-exchange loss was €1.1 million, versus €0.02 million in 2019. Research and development represented the largest operating expense.
Financing activities provided €101.2 million in 2020, mainly from Series B and C share issuances. Subsequent to year-end, the February 2021 IPO raised $176.9 million net. Management said existing cash plus IPO proceeds were expected to fund operations for at least 24 months; this is an estimate dependent on development costs and other assumptions. Service-contract commitments were €11.4 million, including €8.9 million due within one year. The company reported no off-balance-sheet arrangements beyond disclosed commitments and no contingent liabilities at year-end.
Material changes and outlook
- Compared with 2019, operating expenses rose 212% and net loss rose 224%, while operating cash use increased 222%. Management attributed the increase chiefly to advancing PHA121 development and growing the company.
- Management forecast 2021 research and development expense of €50–60 million, with further increases expected as PHVS416 and PHVS719 advance.
- Management expected RAPIDe-1 Phase 2 data in 2022 and planned Phase 2 prophylaxis work with PHVS416 and Phase 1 work for PHVS719 in 2021. These were forward-looking plans, not reported outcomes.
- Management described Phase 1 results as showing oral bioavailability, tolerability at tested doses and proof-of-mechanism in a bradykinin challenge. Comparisons suggesting advantages over icatibant are based on separate studies and modeling, not a head-to-head clinical trial; efficacy in HAE patients had not yet been demonstrated.
Risks, contingencies and unusual items
- Development and funding: The company has no revenue, has accumulated significant losses and expects continuing losses and negative operating cash flow. It remains dependent on capital access; delays or unfavorable financing terms could force program reductions.
- Clinical, regulatory and commercial uncertainty: PHVS416 and PHVS719 were early-stage candidates, with no Phase 2 efficacy data at the time of filing. Trial failure, safety issues, enrollment, approval, pricing, reimbursement and competition could materially affect prospects.
- COVID-19 and supply: COVID-19 delayed enrollment in a Phase 1 multiple-ascending-dose study by about two months and could further disrupt trials, regulators, suppliers and financing. The filing also notes a packaging issue identified at a contract manufacturer in early 2021; it was investigated and RAPIDe-1 began in February 2021.
- Manufacturing and licensing: Pharvaris relies on third parties, including a single CDMO for certain API production. Under its AnalytiCon license, up to €11 million in development, regulatory and sales milestones remained potentially payable, plus royalties; specified breaches could jeopardize licensed rights.
- Internal controls: Management concluded disclosure controls were ineffective due to material weaknesses, including insufficient documented financial controls, monitoring and appropriately staffed accounting/reporting functions. Remediation was planned but not completed; the auditor did not provide an internal-control attestation.
- Other exposures: Currency fluctuations, data privacy and cybersecurity, intellectual-property disputes, product liability, healthcare price controls, and possible PFIC tax treatment for U.S. investors were identified as risks. No material litigation or contingent liabilities were reported for the period.
Most important facts for investors to verify
- Whether RAPIDe-1 and planned prophylaxis studies met timelines, enrolled adequately, and produced clinically meaningful safety and efficacy results.
- Whether cash burn, the stated post-IPO runway and the €50–60 million 2021 R&D forecast aligned with subsequent filings and actual spending.
- Whether the material weaknesses in internal control were remediated and whether later reports identify additional control issues.
- Whether manufacturing capacity, the early-2021 packaging issue, and the AnalytiCon license obligations create further delays or costs.
- Whether market, pricing, reimbursement and competitive assumptions—including comparisons with icatibant—are supported by clinical evidence and regulatory decisions.